Treatment of refractory hypocomplementaemic urticarial vasculitis syndrome progressing to systemic lupus erythematosus with belimumab

Clin Exp Rheumatol. 2022 May;40(4):854-855. doi: 10.55563/clinexprheumatol/m9dexe. Epub 2021 Nov 17.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Humans
  • Lupus Erythematosus, Systemic* / complications
  • Lupus Erythematosus, Systemic* / diagnosis
  • Lupus Erythematosus, Systemic* / drug therapy
  • Urticaria* / diagnosis
  • Urticaria* / drug therapy
  • Urticaria* / etiology
  • Vasculitis* / diagnosis
  • Vasculitis* / drug therapy

Substances

  • Antibodies, Monoclonal, Humanized
  • belimumab